İleri evre yaşlı küçük hücreli dışı akciğer kanseri hastalarının tedavisinde sisplatin ve etoposid
Date
2003-04-21
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Bu çalışmanın amaçları 70 yaş ve üzeri ileri evre küçük hücreli dışı akciğer kanseri (KHDAK) hastalarında sisplatin ve etoposid tedavisinin aktivitesini ve tolerabilitesini araştırmaktı. Yirmi dört hasta çalışmaya alındı. Sisplatin 60 mg/m2 dozunda 1. günde ve etoposid 120 mg/m2 dozunda 1-3. günlerde verildi. Toplam 116 siklus uygulandı. On iki (%50) hasta altı siklus tedaviyi tamamladı. Üç hastada (%12.5) kısmi yanıt elde edilirken, 12 hastada (%50) stabil hastalık ve 9 hastada (%37.5) progresyon mevcuttu. Ortalama sağ kalım 48.5 ± 6.06 hafta ve 1 yıllık sağ kalım oranı %38’di. Grade 3-4 nötropeni hastaların %16.6’ında, grade 4 trombositopeni %4.1’nde ve grade 1-2 nöropati %25’inde görüldü. Bir hastada grade 3 nefrotoksisite nedeniyle tedavi sonlandırıldı. Sonuç olarak sisplatin ve etoposid yaşlı KHDAK hastalarının tedavisinde aktiftir ve nisbeten iyi tolere edilmektedir. Yeni, aktif ve iyi tolere edilen rejimler mevcut sonuçları iyileştirebilir.
The aims of the present study were to test activity and tolerability of cisplatin and etoposide in advanced non-small cell lung cancer (NSCLC) patients aged 70 years or higher. Twenty-four patients were enrolled. Cisplatin was given at a dose of 60 mg/m2 on day 1 and etoposide at a dose of 120 mg/m2 on days 1-3. Total 116 courses were administered. Twelve patients (50%) completed all six cycles of treatment. Three patients (12.5%) obtained a partial response, as well as 12 (50%) stable disease and 9 (37.5%) progressive disease. The median survival was 48.5 ± 6.06 weeks, and the 1 year survival rate was 38%. Grade 3-4 neutropenia occurred in 16.6% of patients, grade 4 thrombocytopenia in %4.1, and grade 1-2 neuropathy in 25%. One patient discontinued treatment due to grade 3 nephrotoxicity. In conclusion, cisplatin and etoposide regimen is active and relatively well-tolerated in the treatment of elderly NSCLC patients. New, active and well-tolerated combination regimens could improve present results.
The aims of the present study were to test activity and tolerability of cisplatin and etoposide in advanced non-small cell lung cancer (NSCLC) patients aged 70 years or higher. Twenty-four patients were enrolled. Cisplatin was given at a dose of 60 mg/m2 on day 1 and etoposide at a dose of 120 mg/m2 on days 1-3. Total 116 courses were administered. Twelve patients (50%) completed all six cycles of treatment. Three patients (12.5%) obtained a partial response, as well as 12 (50%) stable disease and 9 (37.5%) progressive disease. The median survival was 48.5 ± 6.06 weeks, and the 1 year survival rate was 38%. Grade 3-4 neutropenia occurred in 16.6% of patients, grade 4 thrombocytopenia in %4.1, and grade 1-2 neuropathy in 25%. One patient discontinued treatment due to grade 3 nephrotoxicity. In conclusion, cisplatin and etoposide regimen is active and relatively well-tolerated in the treatment of elderly NSCLC patients. New, active and well-tolerated combination regimens could improve present results.
Description
Keywords
Küçük hücreli dışı akciğer kanseri, Kemoterapi, Yaşlı hastalar, Non-small cell lung cancer, Chemotherapy, Elderly patients
Citation
Kanat, Ö. vd. (2003). ''İleri evre yaşlı küçük hücreli dışı akciğer kanseri hastalarının tedavisinde sisplatin ve etoposid''. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 29(1), 25-28.